Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
March 01 2024 - 9:55AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of March 2024
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc
(the 'Company')
Publication of Annual Report 2023
The Company has today published on its website www.annualreport.gsk.com its
Annual Report for the year ended 31 December 2023 ('Annual Report
2023').
In compliance with Listing Rule 9.6.1R of the UK Financial Conduct
Authority ('FCA'), the Annual Report 2023 has been submitted to the
FCA's National Storage Mechanism ('NSM') and will shortly be
available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
A hard copy version of the Annual Report 2023 and the Notice of
Annual General Meeting 2024 ('AGM Notice') will be sent to those
shareholders who have elected to receive paper communications on or
around 25 March 2024. The AGM Notice will be made available to
shareholders who have not elected to receive paper communications
on the same date.
This announcement is not a substitute for reading the Annual Report
2023 in full.
Additional Information
For the purposes of complying with the FCA's Disclosure and
Transparency Rules ('DTRs') and the requirements imposed on issuers
through the DTRs, information required to be communicated with the
media in unedited full text was included in the Annual Report 2023.
The Annual Report 2023 was submitted to the NSM and will shortly be
available for inspection. It is also available on the Company's
website as noted above.
This announcement is made in accordance with DTR
6.3.5R(1A).
V A Whyte
Company Secretary
1 March 2024
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GSK plc
|
|
(Registrant)
|
|
|
Date: March
01, 2024
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GSK plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Sep 2024 to Oct 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Oct 2023 to Oct 2024